$Humacyte (HUMA.US)$ Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs Humacyte (Nasdaq: HUMA) and Pluristyx have expanded their partnership to advance the development of the BioVascular Pancreas (BVP™), designed to treat insulin-dependent diabetes. Pluristyx will provide gene-edited PluriBank™ iPSC lines with blocked Human Leukocyte Antigen (HLA) markers expression, using their clinical-grade Mad7 gene editing technology. ...
$Humacyte (HUMA.US)$Reuters 1 min ago Humacyte and Pluristyx Announce Gene Editing Partnership to Support Biovascular Pancreas (Bvp™) Development Using Ipscs
$Humacyte (HUMA.US)$ FDA delay in approving Humacyte stemmed from national security concerns - developed in collaboration with the DoD. An undeniable strategic advantage for the U.S. military. The fact that we have a +10 billion $ runway is just nice to know.
1
Report
104983812
:
so it means it got plenty of rooms to rise?
$HUMA 250117 10.00C$ Fresenius, with its stake and rights in Humacyte, could face a bidding war from Baxter, which seeks to expand its hemodialysis portfolio. Both see Humacyte’s innovative vascular technology as key to dominating the dialysis market.
1
1
Report
72839823
:
Huma could be a good buyout if price is right.
NOTE! 1. NFA 2. Do not open position without chart confirmation, indicators, momentum. 3. Check current shorts availability on FINTEL.io 4. Scale out and secure profits. GREED will make losr and get trapped. 5. Always remember shorts include dark pools. 6. Most importantly, DON’T BLAME ME for your losses. I already give watchlist and stock education. The ball is on you. I give you “watchlist” which means its on watch for me, not an open po...
Humacyte Stock Forum
Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs
Humacyte (Nasdaq: HUMA) and Pluristyx have expanded their partnership to advance the development of the BioVascular Pancreas (BVP™), designed to treat insulin-dependent diabetes. Pluristyx will provide gene-edited PluriBank™ iPSC lines with blocked Human Leukocyte Antigen (HLA) markers expression, using their clinical-grade Mad7 gene editing technology.
...
1 min ago
Humacyte and Pluristyx Announce Gene Editing Partnership to Support Biovascular Pancreas (Bvp™) Development Using Ipscs
FDA delay in approving Humacyte stemmed from national security concerns - developed in collaboration with the DoD. An undeniable strategic advantage for the U.S. military.
The fact that we have a +10 billion $ runway is just nice to know.
Fresenius, with its stake and rights in Humacyte, could face a bidding war from Baxter, which seeks to expand its hemodialysis portfolio. Both see Humacyte’s innovative vascular technology as key to dominating the dialysis market.
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits. GREED will make losr and get trapped.
5. Always remember shorts include dark pools.
6. Most importantly, DON’T BLAME ME for your losses. I already give watchlist and stock education. The ball is on you. I give you “watchlist” which means its on watch for me, not an open po...
No comment yet